Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Go back to Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 58.06 -2.91 (4.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $60.97 | 52 Week High | $19.98 | |||
| Open | $60.40 | 52 Week Low | $10.52 | |||
| Day High | $61.00 | P/E | N/A | |||
| Day Low | $57.94 | EPS | $-1.45 | |||
| Volume | 342,354 | |||||
